A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
{{output}}
The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this... ...
